Myelodysplastic syndrome from theoretical review to clinical application view
Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essen...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/397 |
| _version_ | 1797963886806171648 |
|---|---|
| author | Amrallah A. Mohammad |
| author_facet | Amrallah A. Mohammad |
| author_sort | Amrallah A. Mohammad |
| collection | DOAJ |
| description | Myelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction. |
| first_indexed | 2024-04-11T01:35:18Z |
| format | Article |
| id | doaj.art-f3c9cccb2fd04f6bbde357d3f33bcc35 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:35:18Z |
| publishDate | 2018-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-f3c9cccb2fd04f6bbde357d3f33bcc352023-01-03T09:00:18ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652018-12-0112210.4081/oncol.2018.397Myelodysplastic syndrome from theoretical review to clinical application viewAmrallah A. Mohammad0Medical Oncology, Department of Medical Oncology, Faculty of Medicine, Zagazig UniversityMyelodysplastic syndromes (MDS), called ineffective hematopoiesis is indicated by bone marrow failure and tendency to acute myeloid leukemia transformation. Since the disease is more common in elderly with non- hematology co-morbidities, the research for less toxic and curative novel agents is essential. More than 12 years without new Food and Drug Administration approved drugs in MDS management through the whole course, only 5 drugs. We summarized the basic data in diagnosis, treatment guidelines and future direction.https://www.oncologyreviews.org/index.php/or/article/view/397Myelodysplastic syndromelenalidomidehypomethyating agents. |
| spellingShingle | Amrallah A. Mohammad Myelodysplastic syndrome from theoretical review to clinical application view Oncology Reviews Myelodysplastic syndrome lenalidomide hypomethyating agents. |
| title | Myelodysplastic syndrome from theoretical review to clinical application view |
| title_full | Myelodysplastic syndrome from theoretical review to clinical application view |
| title_fullStr | Myelodysplastic syndrome from theoretical review to clinical application view |
| title_full_unstemmed | Myelodysplastic syndrome from theoretical review to clinical application view |
| title_short | Myelodysplastic syndrome from theoretical review to clinical application view |
| title_sort | myelodysplastic syndrome from theoretical review to clinical application view |
| topic | Myelodysplastic syndrome lenalidomide hypomethyating agents. |
| url | https://www.oncologyreviews.org/index.php/or/article/view/397 |
| work_keys_str_mv | AT amrallahamohammad myelodysplasticsyndromefromtheoreticalreviewtoclinicalapplicationview |